NYMXF NYMOX PHARMACEUTICAL CORP IFRS
In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY49.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-701.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,135.9%
Debt / equity—
Current ratio0.09x
Interest coverage-18.95x
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-295.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| Cost of revenue | — | $0 |
| Gross profit | — | $0 |
| R&D expense | $3.28M | $3.99M |
| SG&A expense | $1.00M | $4.36M |
| Operating income | -$4.28M | -$8.35M |
| Interest expense | $226,000 | $58,000 |
| Pretax income | -$4.49M | -$8.84M |
| Income tax | $0 | $0 |
| Net income | -$4.49M | -$8.84M |
| EPS (basic) | -0.05 | -0.10 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $74,000 | $70,000 |
| Receivables | $0 | $0 |
| Current assets | $653,000 | $625,000 |
| PP&E, netmay include right-of-use assets (IFRS) | $1,000 | $2,000 |
| Total assets | $654,000 | $627,000 |
| Current liabilities | $7.43M | $3.80M |
| Total liabilities | $7.43M | $3.80M |
| Shareholders' equity | -$6.78M | -$3.17M |
| Shares outstanding | 94.54M | 93.54M |
| Cash flow statement | ||
| Operating cash flow | -$2.60M | -$4.06M |
| Capital expenditure | $0 | $3,000 |
| Free cash flow | -$2.60M | -$4.06M |
| Investing cash flow | $0 | -$3,000 |
| Financing cash flow | $2.60M | $2.73M |
| Stock-based compensation | $671,000 | $3.36M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.